The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...
The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.
Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...
The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...
MedPage Today on MSN
First Twice-Yearly Biologic Approved for Severe Eosinophilic Asthma
The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...
With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | Tuesday ...
The US FDA has approved depemokimab as an add-on maintenance therapy for individuals aged 12 years or older with severe asthma, according to a press release from manufacturer GlaxoSmithKline.
The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.
The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...
Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...
The FDA has approved GSK’s Exdensur (depemokimab-ulaa) as an add-on maintenance therapy for adolescents and adults with severe asthma characterized by an eosinophilic phenotype. 1 ...
Among adults with evidence of systemic mast cell activation, bone marrow samples allowed for detection of 13 additional patients with the KIT D816V mutation that were not detected in peripheral blood, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback